Scientific Poster
Wendell Jones, Ph.D. | November 12, 2018

A Pan-Cancer View of the Immune Landscape in the Tumor Microenvironment via RNA and their Potential for Biomarkers in Clinical Trials 

Immune-based biomarkers for measurement of tumor microenviornment (TME)
Author: Wendell Jones

Immune-based biomarkers are now commonly available when measuring the tumor microenvironment (TME), although many are based on immuno-histochemistry methods which sometimes have drawbacks: specificity, quantitation, variety. In addition, next-gen RNA sequencing and focused RNA assays are now much more accessible (for example, processing formalin-fixated material has a much higher degree of success) and are commonly employed in clinical trials to measure tumor activity and immune cell content in the TME. Download our poster from SITC 2018 to learn about our gene signatures for immune activity.

Related Services:
Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy

Gene expression and analysis for detection of 15 Immune Landscape Signatures

T-cell Receptor (TCR) Sequencing Assay for Characterization of Adaptive Immune Response

Detects TCRβ and TCRγ clonotypes expressed at the mRNA level

Microsatellite Instability Assay for Response to Immunotherapy

MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens

Read More